---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107295"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:35:18.924043+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health Q2 2025 net loss $27.9M; $23M offering extends cash runway into 2026

## Summary
- Net loss for Q2 2025 was $27.9 million, compared to $17.2 million in Q2 2024, driven by higher R&D spending and non-cash changes.
- Completed $23 million underwritten public offering in August 2025, with potential additional $46 million from warrants.
- Cash and cash equivalents were $22.3 million as of June 30, 2025; post-offering cash runway extends into 2026.
- Positive 3-month REVEAL-1 Cohort data: 12 of 13 participants maintained weight after GLP-1 discontinuation with Revita.
- Enrollment completed for REMAIN-1 Midpoint Cohort (45 participants); 3-month randomized data expected September 2025.

## SEC filing metadata
- accession: 0000950170-25-107295
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017025107295/0000950170-25-107295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017025107295/guts-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107295
- JSON: https://secwatch.observer/filing/0000950170-25-107295.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.